Empower Clinics Inc (CSE:CBDT) (FRA:8EC) (OTCQB:EPWCF) has signed a Memorandum of Understanding (MOU) for a six-month pilot program with Pharmachoice for the distribution and resale of Kai Care COVID-19 testing solutions.
Empower said the products will include Rapid Antigen testing, Rapid Antibody testing, and Saliva RT-PCR tests.
"The expansion to Pharmachoice's network is a phenomenal step forward in our plan to provide Kai Care Testing solutions directly and conveniently to consumers," said Empower CEO Steven McAuley in a statement.
"We are excited to build on this progress through our ongoing advanced conversations with other major pharmacy groups from across North America," McAuley added.
Pharmachoice is a fast-growing, independently-owned Canadian Pharmacy network with more than 900 locations covering the PharmaChoice and RxHealthMed brands. Pharmachoice has a network of over 2,000 pharmacists with nearly two decades of experience.
Empower said the company's local ties across numerous regions make it a great partner in providing direct consumer sales of Kai Care Testing Solutions.
Under the MOU, Empower said it and Pharamchoice have agreed to the six-month pilot program to allow both parties to fully evaluate revenue, marketing, and partnership expansion opportunities. The goal is to determine the optimal business model that will best serve PharmaChoice and its patients.
Empower will provide Pharmachoice not only the tests but express shipping on all ordered units and technical support as well.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham